Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib, Durvalumab, and Aromatase Inhibitor in Neoadjuvant HR+ Breast Cancer
NCT04088032Phase 1Withdrawn
- Sponsor
- Alison Stopeck
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib and durvalumab in breast cancer, sponsored by Alison Stopeck. Primary endpoint: Treatment-Related Adverse Events at 24 weeks. Planned start Oct 2019; status: withdrawn.
02
Drugs
abemaciclibdurvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04088032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088032.